Skip to main content
Tourmaline Bio, Inc. logo

Tourmaline Bio, Inc. — Investor Relations & Filings

Ticker · TRML ISIN · US87410C1045 US Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2024-01-24 Regulatory Filings
Country US United States of America
Listing US TRML

About Tourmaline Bio, Inc.

https://www.tourmalinebio.com/

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with life-altering inflammatory and immune diseases. The company's lead asset is pacibekitug, a monoclonal antibody that targets the interleukin-6 (IL-6) cytokine, a key driver of inflammation. Pacibekitug is being developed as a potential treatment for a range of conditions, with a primary focus on atherosclerotic cardiovascular disease (ASCVD) and other severe autoimmune and inflammatory disorders, aiming to establish a new standard of care in areas with high unmet medical need.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes an announcement of a public offering of common stock, details about a recent merger transaction, and references to attached exhibits including business description, management's discussion and analysis, and unaudited pro forma financial information. The document does not contain full financial statements or detailed financial results itself but rather announces events and includes exhibits. The length is 7302 characters, which is moderate but the content is primarily event announcements and references to other documents. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit the more specific categories like Annual Report, Earnings Release, or Capital/Financing Update directly. Therefore, the best classification is Regulatory Filings (RNS).
2024-01-24 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an Item 7.01 Regulation FD Disclosure about an updated corporate presentation and a press release, both furnished as exhibits. The document does not contain detailed financial statements or comprehensive financial analysis but rather announces the availability of a corporate presentation and press release. The document length is 8102 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on clinical trial plans and forward-looking statements, typical for a current report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2024-01-08 English
FORM 4 SUBMISSION
Director's Dealing
2023-12-15 English
FORM 3 SUBMISSION
Director's Dealing
2023-12-15 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 13, 2023, reporting the appointment of a new director and chair of the board, Clay Siegall. The key section is Item 5.02, which covers departure or appointment of directors or officers. The content focuses on management changes, including board appointments and related compensation. There are no financial statements or earnings data, so it is not an earnings release or financial report. The document is not a proxy statement or voting results announcement. It is clearly an announcement of changes in the company's board of directors and senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (6945 characters) supports it being a full Form 8-K report rather than a brief announcement or certification. Confidence is high due to clear and explicit content about management changes.
2023-12-14 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The key content is the resignation of a director from the board, which is an announcement of a change in the company's board of directors. The relevant section is Item 5.02, which deals with departure and election of directors or officers. The document does not contain financial data or detailed reports but announces a management change. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3244 characters, which is consistent with a typical 8-K announcement rather than a full report.
2023-11-30 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.